Trial Profile
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel; Fludeoxyglucose F-18; Letrozole; Tamoxifen
- Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms PHERGain
- 03 Apr 2024 Results (n=356;data cut-off date: 4 Nov 2022 at a median follow-up of over 43 months) from group/cohort A and B assessing 3-year invasive disease-free survival and safety in HER2-positive early breast cancer published in the Lancet.
- 02 Feb 2024 Planned End Date changed from 1 Nov 2023 to 1 Nov 2026.
- 02 Feb 2024 Status changed from completed to active, no longer recruiting.